CHICAGO, IL—Patients with asymptomatic severe aortic stenosis who are watched until symptoms develop before undergoing TAVI are a greater risk of dying, being hospitalized for heart failure (HF), or ...

From 2015 to 2020, the number of patients opting for valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) over redo surgical aortic valve replacement (SAVR) rose significantly, from 35.3% ...

A transcatheter aortic valve replacement (TAVR) therapy was approved by the US Food and Drug Administration (FDA) for patients with severe aortic stenosis even without symptoms. This is the first FDA ...

At the 2026 Society of Thoracic Surgeons (STS) Annual Meeting, investigators presented a late-breaking study focused on surgical aortic valve replacement (SAVR) following prior transcatheter aortic ...

In December, Edwards Lifesciences persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis, causing the agency to reconsider its previous stance on covering transcatheter ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...

A previous analysis in this trial showed that among patients with severe, symptomatic aortic stenosis who were at low surgical risk, the rate of the composite end point of death, stroke, or ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. For 14 years, patient access to TAVR has been restricted for Medicare beneficiaries under a ...

Of the two heart valve surgeries Janice Smith has had at OhioHealth Mansfield Hospital, the second was much easier for her. "I had a good experience both times," the 86-year-old said. "It's just that ...

CHICAGO, IL — The largest-ever review of transcatheter aortic-valve replacement (TAVR) procedures for failed bioprosthetic valves suggests that TAVR could play a key role in solving a problem that ...